目的：探讨胆管细胞癌患者术后替吉奥化疗的临床效果。方法：选取87例根治术后的胆管细胞癌患者为研究对象，按患者意愿，42例接收术后替吉奥化疗（化疗组），45例不接受化疗（非化疗组），比较两组患者的近期效果及远期预后差异。结果：化疗组化疗后的血清KL-6蛋白、CA19-9、CA125水平较本组化疗前及非化疗组均明显降低（均P<0.05）；化疗过程中主要毒副反应为消化道不良（35.71%）、贫血（14.29%）、色素沉着（14.29%），均为轻度；两组术后1年无瘤生存率、总生存率比较差异均无统计学意义（均P>0.05）；但化疗组术后3年的无瘤生存率、总生存率均明显高于非化疗组（28.57% vs. 11.11%；42.86% vs. 22.22%，均P<0.05）；化疗组患者术后中位无瘤生存时间、总生存时间分别为13.7、21.5个月，均明显长于非化疗组（9.8、16.4个月）（均P<0.05）。结论：胆管细胞癌患者术后采用替吉奥进化疗对于降低肿瘤标志物水平，延长患者的生存时间具有积极作用。
Observation of short- and long-term effects of postoperative chemotherapy with tegafur/gimeracil/oteracil (S-1) on cholangiocarcinoma
Objective: To investigate the clinical efficacy of postoperative chemotherapy with tegafur/gimeracil/oteracil (S-1) in patients with cholangiocarcinoma. Methods: Eighty-seven patients with cholangiocarcinoma after radical resection were selected as study subjects. According to patients’ preferences, 42 cases received postoperative S-1 chemotherapy (chemotherapy group), and 45 cases did not receive any postoperative chemotherapy (non-chemotherapy group). The short-term effects and long-term results between the two groups of patients were compared. Results: The serum levels of KL-6 protein, CA19-9 and CA125 after chemotherapy were significantly reduced in chemotherapy group compared with those in non- chemotherapy group (all P<0.05). The main toxic and side effects during chemotherapy were dyspepsia (35.71%), anemia (14.29%) and pigmentation (14.29%), all of which were minor degrees of severity. The 1-year disease-free survival and overall survival rates showed no statistical difference between the two groups (both P>0.05), but the 3-year disease-free survival and overall survival rates in chemotherapy group were significantly higher than those in non-chemotherapy group (28.57% vs. 11.11%; 42.86% vs. 22.22%, both P<0.05). The median disease-free survival time and overall survival time was 13.7 and 21.5 months respectively, and both were significantly longer than those in non-chemotherapy group (9.8 and 16.4 months) (both P<0.05). Conclusion: In cholangiocarcinoma patients, postoperative S-1 chemotherapy has beneficial effects on reducing tumor marker levels and prolonging survival time.